[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pulmonary-hypertension-due-to-left-heart-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pulmonary-hypertension-due-to-left-heart-disease":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,49,78,102],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100634271","evaluation-of-the-bmpr2-activin-signaling-pathway-in-group-ii-pulmonary-hypertension-100634271",false,"NCT07537517","Evaluation of the BMPR2-Activin Signaling Pathway in Group II Pulmonary Hypertension.","Evaluation of the BMPR2-Activin Signaling Pathway as a Key Mediator in Group II Pulmonary Hypertension. BREATHE-PH Study","BREATHE-PH","Inclusion Criteria:\n\n* Older that 18 years\n* Heart failled patients with clinical indication for invasive hemodynamic assessment\n* Written consent\n\nExclusion Criteria:\n\n* Refulsl to sign the infomred consent\n* Presence of iodinated contrast allergy\n* Ineligibility for HT (for BREATHE-CT substudy)","ALL","18 Years",{"count":20,"type":21},150,"ESTIMATED","12 Months","OBSERVATIONAL","Previous data from our group showed reduced BMPR2 isoform A in pulmonary hypertension associated with left heart disease (PH-LHD) of valvular origin.\n\nFocusing on dysregulation of the BMPR2-activin pathway, a key regulator of vascular homeostasis, this project uses a multimodal approach combining molecular biology, advanced cardiac imaging, and histology.\n\nIts aim is to determine the role of the BMPR2-activin pathway in the development and regression of PH-LHD.\n\nWe will conduct a prospective observational study with 1-year follow-up in 150 heart failure patients of different etiologies undergoing hemodynamic assessment.\n\nClinical parameters, biomarkers, molecular profiles, and hemodynamic\u002Fechocardiographic variables will be analyzed.\n\nA nested substudy in 40 heart transplant candidates will include thoracic CT for vascular morphometric analysis and histological correlation in explanted hearts versus healthy controls.\n\nWe will also assess reversibility of vascular remodeling one year after transplantation.\n\nResults may redefine PH-LHD classification, enable phenotypic precision-medicine models, guide targeted therapies such as activin inhibitors, and refine transplant criteria in combined pulmonary hypertension.",[26,27,28],"Pulmonary Hypertension Due to Left Heart Disease","Pulmonary Hypertension (PH)","Heart Failure",[30,31,32,33,34,35],"BMPR2","Activin","cardiac transplant","pulomnary hypertension II","gene expression","microRNAs","RECRUITING","2026-04-16",{"date":39,"type":40},"2026-04-17","ACTUAL",{"date":42,"type":40},"2025-11-01",{"date":44,"type":21},"2028-12-31",{"name":46,"class":47},"Hospital General Universitario Gregorio Marañon","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":56,"targetDuration":58,"studyType":23,"phases":4,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":48},"100424568","pulmonary-hypertension-biorepository-and-registry-100424568","NCT04808596","Pulmonary Hypertension Biorepository and Registry","PHBR","Inclusion Criteria:\n\n1. The participant is a patient at TUKHS or has agreed to participate in a study approved by the KUMC Human Research Protection Program (HRPP)\n2. The participant has a diagnosis of pulmonary hypertension confirmed by right heart catheterization\n3. Patient is ≥ 18 years of age or older\n\nExclusion Criteria:\n\n1. Participant declines to participate (living patients only)\n2. Participant is unable to provide informed consent (living patients only)",{"count":57,"type":21},300,"6 Months","Establish a pulmonary hypertension registry and biorepository to lead towards a further understanding of the disease.",[61,62,26,63,64,65,66,67,68],"Pulmonary Hypertension","Pulmonary Arterial Hypertension","Pulmonary Hypertension, Primary","Pulmonary Hypertension Due to Lung Diseases and Hypoxia","Pulmonary Hypertension, Primary, 4","Pulmonary Hypertension, Primary, 2","Pulmonary Hypertension, Primary, 3","Chronic Thromboembolic Pulmonary Hypertension","2025-07-29",{"date":71,"type":40},"2025-08-01",{"date":73,"type":40},"2020-08-10",{"date":75,"type":21},"2027-07-31",{"name":77,"class":47},"University of Kansas Medical Center",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":87,"phases":88,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":48},"100399703","phase-4-inhaled-and-intravenous-milrinone-in-patients-with-severe-pulmonary-hypertension-100399703","NCT04484675","Inhaled and Intravenous Milrinone in Patients With Severe Pulmonary Hypertension","Comparative Study Between Inhaled and Intravenous Milrinone in Patients With Severe Pulmonary Hypertension Undergoing Cardiac Surgery","Inclusion Criteria:\n\n* Patients scheduled to undergo mitral valve surgery by cardiopulmonary bypass with estimated mean pulmonary artery pressure =\\>55 estimated by using preoperative Doppler echocardiography\n\nExclusion Criteria:\n\nPatients were excluded if they had surgery without CPB, preoperative hemodynamic instability (defined as acute requirement for vasoactive support or mechanical device),Patients with severe LV dysfunction (LV ejection fraction of less than 30% congenital heart disease, a contraindication to transesophageal echocardiography (TEE), emergency surgery or re-do surgeries severe renal or hepatic disease\n\n, coagulopathy, and thromboembolic disease treated with anticoagulants",{"count":86,"type":21},38,"INTERVENTIONAL",[89],"PHASE4","The investigator compared difference between inhaled and intravenous milirinone in patiens with severe pulmonary hypertension undergoing cardiac surgery",[26],"2025-04-26",{"date":94,"type":40},"2025-04-30",{"date":96,"type":40},"2023-05-20",{"date":98,"type":21},"2025-05-10",{"name":100,"class":101},"Zagazig University","OTHER_GOV",{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":87,"phases":112,"briefSummary":114,"conditions":115,"keywords":4,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":127},"100474925","training-in-hfpef-ph-100474925","NCT05464238","Training in HFpEF-PH","Implementation, Safety, Tolerability and Effect of Exercise and Respiratory Training on 6-minute Walking Distance in Patients With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction (HFpEF): a Randomized Controlled Multicenter Trial in European Countries.","TRAIN HFpEF","Inclusion Criteria:\n\n1. Female and male patients ≥18 years\n2. WHO\u002FNYHA functional class II - IV\n3. PH with HFpEF diagnosed by right heart catheterisation showing:\n\n   mean pulmonary arterial pressure (mPAP) ≥25mmHg at rest; pulmonary arterial wedge pressure (PAWP) ≥15mmHg at rest or LVEDP ≥16mmHg and\u002For PAWP≥25 mmHg during exercise, and\n4. Preserved left ventricular ejection fraction ≥50%\n5. Patients receiving optimized therapy including intensified treatment with diuretics and who have been stable for 1 month before entering the study.\n6. Except for diuretics, medical treatment should not be changed during the study period.\n7. Able to understand and willing to sign the Informed Consent Form\n\nExclusion Criteria:\n\n1. Pre-capillary pulmonary hypertension (Group I; Group III; Group IV; Group V according to PH guidelines)\n2. Congenital or acquired severe valvular diseases (severe aortic stenosis or insufficiency, severe mitral valve stenosis or insufficiency)\n3. Pregnancy or lactation\n4. Walking disability\n5. Subject who participates in an interventional study during the course of this study\n6. Severe lung disease: FEV1\u002FFVC \\\u003C0.5 and total lung capacity \\\u003C60% of the normal value\n7. Active myocarditis, unstable angina pectoris, exercise induced ventricular arrhythmias, active liver disease, porphyria or elevations of serum transaminases \\>3 x ULN (upper limit of normal) or bilirubin \\>1.5 x ULN\n8. Haemoglobin concentration less than 75% of the lower limit of normal\n9. Systolic blood pressure \\\u003C85 mmHg\n10. History or suspicion of inability to cooperate adequately.",{"count":111,"type":21},90,[113],"NA","Exercise interventions alone or as a component of a comprehensive cardiac rehabilitation program for patients with heart failure (HFrEF and HFpEF) have already shown to reduce the risk of hospitalisations due to HF and improved exercise capacity and health-related quality of life. Two meta-analyses have confirmed the beneficial effects in cardiorespiratory fitness and quality of life. The effects of exercise training on systolic and diastolic function remain inconclusive. Due to the positive results of exercise training in HFpEF, cardiac rehabilitation is recommended (Class I, level A) to be integrated into the overall provision of HF care. However, none of these studies focused on concomitant PH in HFpEF.\n\nExercise training in patients with pulmonary hypertension has already shown to improve exercise capacity, quality of life and peak oxygen consumption, which was confirmed by three meta-analyses and a Cochrane review. Though different diagnostic subgroups have already been enrolled in PH exercise training studies, they mainly included pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Data on combined PH and HFpEF is still lacking.\n\nAs recently pointed out by Arena et al. there may thus be an exercise training volume\u002Fintensity which may be detrimental to the RV in patients with HF and concomitant PH.\n\nThis study is sought to investigate whether a specialized training program is safe and tolerable and may improve exercise capacity, quality of life, hemodynamics, diastolic dysfunction and biomarkers in patients with PH and HFpEF.",[26,116],"Heart Failure With Preserved Ejection Fraction","NOT_YET_RECRUITING","2022-09-14",{"date":120,"type":40},"2022-09-16",{"date":122,"type":21},"2023-02-01",{"date":124,"type":21},"2026-12",{"name":126,"class":47},"Heidelberg University",2]